Skip to main content
    P

    Pharming Group NV (PHAR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $12.06
    -0.53 (-4.21%)

    Market Cap: $891.80M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Pharming Group NV (PHAR) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Pharming Group NV (PHAR) has a market cap of $891.80M and an enterprise value of $802.17M. Revenue fell 99.58% over the last 12 months from the 12 months before. Its share count is up 11.60% from a year earlier.

    Total Valuation

    Enterprise value is 10.05% below the market cap, as cash exceeds debt.

    Market Cap$891.80M
    Enterprise Value$802.17M
    Latest price (Nov 17, 2026)$12.06

    Key Dates

    Last Earnings DateOct 27, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 6.45% in the quarter ended Sep 30, 2026 and grew 7.49% a year over 2 years.

    Shares Outstanding74.67M
    Shares Change (YoY)+11.60%
    Shares Change (QoQ)+6.45%
    Share Count Growth (2Y CAGR)+7.49%

    Valuation Ratios

    Sales and book value multiples are 2.3x and 3.1x. Its year-end P/E ranged from 39.9x to 252.4x from 2020 to 2025.

    P/E Ratio37.7x
    P/S Ratio2.3x
    Forward P/S2.3x
    P/B Ratio3.1x
    P/TBV Ratio5.4x
    P/FCF Ratio28.4x
    P/OCF Ratio27.4x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 14.5x EBITDA and 25.6x free cash flow.

    EV / Earnings33.2x
    EV / Sales2.1x
    EV / EBITDA14.5x
    EV / EBIT18.3x
    EV / FCF25.6x

    Price Statistics

    The stock is down 28.26% over 52 weeks and trades 9.64% above its 50-day average.

    Beta (1Y)0.90
    52-Week Change-28.26%
    1-Month Change+32.38%
    3-Month Change+1.77%
    6-Month Change-4.29%
    5-Year Change+35.89%
    Total Return (1Y)-28.26%
    Total Return (3Y CAGR)+1.16%
    Total Return (5Y CAGR)+6.49%
    Return vs SPY (1Y)-35.76%
    Max Drawdown (1Y)-56.99%
    Max Drawdown (3Y)-56.99%
    Sharpe Ratio (1Y)-0.45
    Correlation with SPY (1Y)0.20
    50-Day Average$11.00
    200-Day Average$13.38
    52-Week Range$9.11 to $21.34
    RSI (14 Days)52.0
    Average Volume (20 Days)17.19K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.23x current liabilities, and total debt is 0.34x shareholder equity.

    Current Ratio3.23x
    Quick Ratio2.65x
    Debt / Equity0.34x
    Debt / EBITDA1.79x
    Debt / FCF3.16x
    Interest Coverage4.61x

    Returns and Efficiency

    Return on invested capital is 7.89% over the last 12 months, against a 5-year average of 2.76%.

    Return on Equity (ROE)8.29%
    Return on Assets (ROA)4.86%
    Return on Invested Capital (ROIC)7.89%
    Return on Capital Employed (ROCE)11.05%
    ROE (5Y Average)1.01%
    ROA (5Y Average)0.44%
    ROIC (5Y Average)2.76%
    Asset Turnover0.86x
    Inventory Turnover0.93x
    Receivables Turnover5.87x
    Cash Conversion Cycle-93 days

    Taxes

    Income tax took 29.64% of pretax income over the last 12 months.

    Income Tax (TTM)$10.18M
    Effective Tax Rate29.64%

    Scores

    PHAR has an Altman Z-Score of 3.52, in the safe zone above 2.99, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.

    Altman Z-Score3.52
    Altman Z ZoneSafe
    Piotroski F-Score6 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $386.72M over the last 12 months.

    Revenue$386.72M
    Revenue Growth (YoY)-99.58%
    Gross Profit$329.06M
    Operating Income$26.49M
    Pretax Income$34.33M
    Net Income$24.15M
    EBITDA$55.79M
    EBIT$43.84M
    Reported EPS (TTM)$0.32

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 58.64% of the $496.64M in total assets.

    Cash and Equivalents$189.56M
    Total Debt$99.93M
    Net Cash$89.63M
    Working Capital$222.43M
    Shareholder Equity$291.24M
    Tangible Book Value$165.57M
    Total Assets$496.64M
    Total Liabilities$205.40M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $869.40K of capital spending, operating cash flow left $31.65M of free cash flow.

    Operating Cash Flow$32.52M
    Capital Expenditures$869.40K
    Free Cash Flow$31.65M
    FCF Per Share$0.45
    Depreciation and Amortization$12.13M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 6.85%, against a 5-year average of 1.92%.

    Gross Margin85.09%
    Operating Margin6.85%
    Pretax Margin8.88%
    Net Margin6.25%
    EBITDA Margin14.43%
    EBIT Margin11.34%
    FCF Margin8.19%
    Gross Margin (5Y Average)89.31%
    Operating Margin (5Y Average)1.92%
    Net Margin (5Y Average)1.43%

    Growth

    Revenue grew 22.30% a year over 3 years.

    Revenue Growth (3Y CAGR)+22.30%
    Revenue Growth (5Y CAGR)+12.13%
    EPS Growth (5Y CAGR)-14.72%
    FCF Growth (3Y CAGR)+38.11%
    FCF Growth (5Y CAGR)-4.61%
    Operating Income Growth (3Y CAGR)+28.42%

    Revenue and profit by year

    Dividends and Yields

    PHAR does not pay a dividend. Its free cash flow yield is 3.52%.

    Earnings Yield2.65%
    FCF Yield3.52%
    Shareholder Yield0.00%

    Peer Position

    Against 3 similar companies, PHAR has the 2nd highest P/E.

    P/E Ratio37.7x vs 13.9x median
    P/S Ratio2.3x vs 3.5x median
    ROIC7.89% vs -16.38% median
    Revenue Growth (Trailing 4 Quarters, YoY)-99.58% vs +15.80% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 19.00% and EPS growth at 76.53% a year over the next 5 fiscal years.

    Revenue Growth Forecast (5Y CAGR)+19.00%
    EPS Growth Forecast (5Y CAGR)+76.53%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About PHAR

    What is PHAR's market cap?

    Pharming Group NV has a market cap of $891.80M. Its enterprise value, which adds debt and subtracts cash, is $802.17M.

    What is PHAR's P/E ratio?

    Pharming Group NV has a trailing P/E ratio of 37.7x.

    How many shares of PHAR are outstanding?

    Pharming Group NV has 74.67M shares outstanding. The count is up 11.60% from a year earlier.

    Does PHAR pay a dividend?

    No. Pharming Group NV does not pay a dividend.

    How much debt does PHAR have?

    Pharming Group NV has $99.93M of total debt and $189.56M of cash and equivalents, a net cash position of $89.63M.